These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 21858833)

  • 1. Neoadjuvant therapy for high-risk bulky regional melanoma.
    Tarhini AA; Pahuja S; Kirkwood JM
    J Surg Oncol; 2011 Sep; 104(4):386-90. PubMed ID: 21858833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses.
    Moschos SJ; Edington HD; Land SR; Rao UN; Jukic D; Shipe-Spotloe J; Kirkwood JM
    J Clin Oncol; 2006 Jul; 24(19):3164-71. PubMed ID: 16809739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach.
    Davar D; Tarhini AA; Kirkwood JM
    Clin Dermatol; 2013; 31(3):237-50. PubMed ID: 23608443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon Alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon Alfa-2b treatment.
    Bramlette TB; Lawson DH; Washington CV; Veledar E; Johns BR; Brisman SF; Abramova L; Chen SC
    Dermatol Surg; 2007 Jan; 33(1):11-6. PubMed ID: 17214673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Where are we with adjuvant therapy of stage III and IV melanoma in 2009?
    Fecher LA; Flaherty KT
    J Natl Compr Canc Netw; 2009 Mar; 7(3):295-304. PubMed ID: 19401062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.
    Lewis KD; Robinson WA; McCarter M; Pearlman N; O'Day SJ; Anderson C; Amatruda TT; Baron A; Zeng C; Becker M; Dollarhide S; Matijevich K; Gonzalez R
    J Clin Oncol; 2006 Jul; 24(19):3157-63. PubMed ID: 16809738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant and neoadjuvant therapy for gastric cancer.
    Kelsen DP
    Semin Oncol; 1996 Jun; 23(3):379-89. PubMed ID: 8658222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multidisciplinary treatment strategies in high-risk resectable melanoma: Role of adjuvant and neoadjuvant therapy.
    McKean MA; Amaria RN
    Cancer Treat Rev; 2018 Nov; 70():144-153. PubMed ID: 30195813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanoma adjuvant therapy.
    Tarhini AA; Thalanayar PM
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):471-89. PubMed ID: 24880942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant therapy of stage IIIb melanoma with interferon alfa-2b: clinical and immunological relevance.
    Doveil GC; Fierro MT; Novelli M; Appino A; Bertero M; Quaglino P; Bernengo MG
    Dermatology; 1995; 191(3):234-9. PubMed ID: 8534942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The adjuvant treatment of malignant melanoma.
    Reintgen D; Kirkwood J
    J Fla Med Assoc; 1997 Mar; 84(3):147-52. PubMed ID: 9143164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [High-dose interferon alpha in treatment of patients with malignant melanoma, monitoring of predictive and prognostic biomarkers].
    Vanásková J; Grim J; Kopecký J; Kubala E; Filip S
    Klin Onkol; 2011; 24(3):180-6. PubMed ID: 21717787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges and Opportunities of Neoadjuvant Treatment in Locally Advanced Melanoma.
    McKean MA; Amaria RN
    Am J Clin Dermatol; 2018 Oct; 19(5):639-646. PubMed ID: 30039289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant therapy for melanoma: a promising therapeutic approach and an ideal platform in drug development.
    Tarhini AA
    Am Soc Clin Oncol Educ Book; 2015; ():e535-42. PubMed ID: 25993220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermediate- and high-risk melanoma.
    Agarwala SS
    Curr Treat Options Oncol; 2002 Jun; 3(3):205-17. PubMed ID: 12057066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696.
    Kirkwood JM; Ibrahim J; Lawson DH; Atkins MB; Agarwala SS; Collins K; Mascari R; Morrissey DM; Chapman PB
    J Clin Oncol; 2001 Mar; 19(5):1430-6. PubMed ID: 11230488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High frequency of brain metastases after adjuvant therapy for high-risk melanoma.
    Samlowski WE; Moon J; Witter M; Atkins MB; Kirkwood JM; Othus M; Ribas A; Sondak VK; Flaherty LE
    Cancer Med; 2017 Nov; 6(11):2576-2585. PubMed ID: 28994212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (Neo)adjuvant systemic therapy for melanoma.
    van Zeijl MC; van den Eertwegh AJ; Haanen JB; Wouters MW
    Eur J Surg Oncol; 2017 Mar; 43(3):534-543. PubMed ID: 27453302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant Treatments for Advanced Resectable Melanoma.
    Liu JY; Lowe M
    J Surg Oncol; 2019 Jan; 119(2):216-221. PubMed ID: 30589079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A neoadjuvant biochemotherapy approach to stage III melanoma: analysis of surgical outcomes.
    Kounalakis N; Gao D; Gonzalez R; Becker M; Lewis K; Poust J; Pearlman N; Robinson W; McCarter M
    Immunotherapy; 2012 Jul; 4(7):679-86. PubMed ID: 22853754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.